Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 22, 2021

Connect Biopharma concludes enrolment in ulcerative colitis therapy trial

The international trial will assess the safety and efficacy of CBP-307 versus placebo in a total of 134 UC patients.

Connect Biopharma has concluded subject enrolment in the Phase II clinical trial of its orally available therapy, CBP-307, in adults with moderate-to-severe ulcerative colitis (UC).

CBP-307 is a small molecule modulator of the sphingosine-1-phosphate 1 receptor (S1P1).

A recognised treatment target, S1P1 is a G-protein coupled receptor that has a key role in T-cell movement regulation out of lymph nodes and into the periphery.

The international, double-blind, randomised, placebo-controlled trial will assess the safety and efficacy of CBP-307 versus placebo.

Being carried out at various centres, including in the US, the trial will enrol a total of 134 participants, who will be given CBP-307 or a placebo for 12 weeks of the induction phase.

A maintenance phase will be initiated subsequently where responders to the drug will receive the treatment for another 36 weeks in a double-blind manner while non-responders will be part of an open-label arm to receive the treatment.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

All subjects enrolled in the trial will also be part of the four-week follow-up phase at the end of the maintenance phase.

Connect Biopharma co-founder and CEO Zheng Wei said: “We are pleased to complete the enrolment of the CBP-307 global Phase II trial in patients with moderate-to-severe UC, our lead clinical programme for our oral S1P1 modulator.

“Despite the recent approval of oral therapies for the treatment of UC, there remains the need for additional safe and effective therapies, and we believe that CBP-307 has the potential to address this unmet need.”

The company anticipates reporting topline data from the induction phase of the study by the end of the first quarter of next year.

A common kind of inflammatory bowel disease, UC leads to chronic large intestine inflammation.

Existing therapeutic options for UC include systemic corticosteroids and immunosuppressants, 5-aminosalicylic acid preparations, injectable drugs and surgical procedures.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU